Skip to main content
      PROs in Spa and PSA: Dr. Rachel Tate ( @uptoTate)

      https://t.co/sUXTXDXrFh

      Dr. John Cush RheumNow

      4 years 5 months ago
      PROs in Spa and PSA: Dr. Rachel Tate ( @uptoTate) https://t.co/sUXTXDXrFh
      RT @KDAO2011: Based on the data, what would you do in a new SLE patient w/LN class IV who is already on a background of

      k dao KDAO2011

      4 years 5 months ago
      Based on the data, what would you do in a new SLE patient w/LN class IV who is already on a background of GC's+HCQ? @rheumnow @kidneydoc101 @Lupusreference
      RT @KDAO2011: The case for starting combo Rx for LN (rather than sequential Rx):
      👉Aurora trial: voclosporin + MMF (

      k dao KDAO2011

      4 years 5 months ago
      The case for starting combo Rx for LN (rather than sequential Rx): 👉Aurora trial: voclosporin + MMF (vs. MMF only) prompt efficacy on proteinuria across all ethnic subgroups, twice more complete renal response , no major safety signals. slide 1/ #EULAR2021 @rheumnow https://t.co/TA5i9ITuL7
      RT @LatikaGupta_: #Digital #rheumatology in the era of #COVID-19: evidently increasing inclination of patients and physi

      Latika LatikaGupta_

      4 years 5 months ago
      #Digital #rheumatology in the era of #COVID-19: evidently increasing inclination of patients and physicians to use digital health apps for recording data- as informed by a national survey by @JK77775 and colleagues #EULAR2021 @ARD_BMJ https://t.co/Uo60qZurhG
      RT @drdavidliew: So it comes down to the grand question: how on earth do we actually monitor disease activity??

      "We sti

      David Liew drdavidliew

      4 years 5 months ago
      So it comes down to the grand question: how on earth do we actually monitor disease activity?? "We still don't have a failsafe algorithm... relapse is both underdiagnosed & overdiagnosed" - @Sarah_L_Mackie The challenge lots of good people are working on! #EULAR2021 @RheumNow https://t.co/PUa6Ly1DQw
      RT @ejdein1: OP0131: Pooled data from TULIP-1 and TULIP-2 show anifrolumab (anti-IFN receptor Ab) show improvement of ra

      Eric Dein ejdein1

      4 years 5 months ago
      OP0131: Pooled data from TULIP-1 and TULIP-2 show anifrolumab (anti-IFN receptor Ab) show improvement of rash and arthritis. Shows promise for drug, particularly in subset of pts with high IFN activity #EULAR2021 @RheumNow https://t.co/sddF2NRlEg
      RT @ARD_BMJ: MUC5B promoter variant is associated with interstitial lung disease.
      Interactions with:
      👉rheumatoid art

      ARD & RMD Open ARD_BMJ

      4 years 5 months ago
      MUC5B promoter variant is associated with interstitial lung disease. Interactions with: 👉rheumatoid arthritis 👉 age 👉 sex Check this Finnish biobank study of 250,000 individuals presented by Antti Palömaki at the Plenary Abstracts Session Wed 02/06 16:15 >LC
      RT @_connectedcare: Patients selected to maximise response & minimise adverse events in RA & PsA trials.

      What i

      Dr Irwin Lim _connectedcare

      4 years 5 months ago
      Patients selected to maximise response & minimise adverse events in RA & PsA trials. What implications does this have when we interpret the data & try to apply in clinic? #EULAR2021 https://t.co/CocKlvjme4
      RT @_connectedcare: Placebo response in PsA trials have more than doubled in last decade.

      Due to patient characteristic

      Dr Irwin Lim _connectedcare

      4 years 5 months ago
      Placebo response in PsA trials have more than doubled in last decade. Due to patient characteristics, patient expectations? Makes it very difficult to compare between trials #EULAR2021 https://t.co/XQk4hqrYN8
      RT @drdavidliew: Drug-induced ANCA-associated vasculitis:
      here are the ones to look for👇
      - hydralazine
      - PTU
      - penici

      David Liew drdavidliew

      4 years 5 months ago
      Drug-induced ANCA-associated vasculitis: here are the ones to look for👇 - hydralazine - PTU - penicillamine - thiamazole - sofosbuvir - minocycline - carbimazole (but then a few others floating about!) VigiBase data POS0118 #EULAR2021 @RheumNow https://t.co/ujgJAJQeKY
      RT @drdavidliew: Worse dentition is associated with worse RA disease activity.

      And that's the tooth!🙄

      from two big

      David Liew drdavidliew

      4 years 5 months ago
      Worse dentition is associated with worse RA disease activity. And that's the tooth!🙄 from two big German cohorts @CallhoffJ POS0026 #EULAR2021 @RheumNow https://t.co/rjCQ6AtQzq
      RT @uptoTate: COAST-V: IXE ⬇️SP-N & spinal pain in r-axSpA pts w/ or w/o ⬆️ CRP or morning stiffness. Pts tr

      Dr. Rachel Tate uptoTate

      4 years 5 months ago

      COAST-V: IXE ⬇️SP-N & spinal pain in r-axSpA pts w/ or w/o ⬆️ CRP or morning stiffness. Pts treated w/ ADA re-randomized to IXE showed further⬇️in SP-N & spinal pain. Poster #POS0901 #EULAR2021 @RheumNow https://t.co/46qiqrohbX https://t.co/uB15oTwztV

      RT @ivanoransky: "But, effectively communicating overdiagnosis is a challenge in light of entrenched beliefs about the b

      Ivan Oransky ivanoransky

      4 years 5 months ago
      "But, effectively communicating overdiagnosis is a challenge in light of entrenched beliefs about the benefits of testing and the culture of current journalism practices." @raymoynihan et al in @BMJ_Open. https://t.co/1DW5OIMh6R
      RT @uptoTate: ERA & JPsA children & adolescents tx'ed w/ SEC, JUNIPERA 104wk data: longer time to flare vs PBO.

      Dr. Rachel Tate uptoTate

      4 years 5 months ago

      ERA & JPsA children & adolescents tx'ed w/ SEC, JUNIPERA 104wk data: longer time to flare vs PBO. NRI analysis: 87.2%, 83.7%, 67.4%, 38.4% and 24.4% achieved JIA ACR 30/50/70/90/100, respectively. No new safety signals. #EULAR2021 @RheumNow Abstract #LB004 https://t.co/reWawBWfqh https://t.co/9gzKKU1xrm

      RT @RichardPAConway: Fascinating talk by Dr Tombetti on the potential use of arterial wall derived microvesicles collect

      Richard Conway RichardPAConway

      4 years 5 months ago
      Fascinating talk by Dr Tombetti on the potential use of arterial wall derived microvesicles collected from plasma as a means of non-invasive liquid biopsy in vasculitis @RheumNow #EULAR2021 Abstr#OP0056 https://t.co/Y6UO2mpjV0
      ×